15th International Podocyte Conference and 2025 ISGD Meeting
June 10 - 13, 2025
Germany
62nd European Renal Association (ERA) Congress 2025
June 6 - 7, 2025
Austria
Patients in DUPLEX Achieved Partial or Complete Remission of Proteinuria Earlier and More Often With Sparsentan vs Irbesartan: Implications for Slowing Progression to Kidney Failure in Focal Segmental Glomerulosclerosis (FSGS)
Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT
American Nephrology Nurses Association (ANNA) National Symposium 2025
May 1 - 4, 2025
OR
Improving Proteinuria With Sparsentan (SPAR) in Patients With IgA Nephropathy (IgAN): A Case Series
National Kidney Foundation (NKF) Spring Clinical Meetings 2025
April 10 - 13, 2025
Boston
Sparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward in Light of the Parasol Initiative
World Congress of Nephrology (WCN) 2025
February 6 - 9, 2025
India
Assessment of Health‐Related Quality of Life in Patients With Cystinuria on Tiopronin Therapy
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS
Implications of Complete Proteinuria Remission at Any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial
Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis